| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:11714251 | IVR | 250 mg/L | 250 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations |
| IVR | 250 mg/L | 250 mg/L | Elevated biliary T4 excretion | Metabolic endocrine-mediated perturbations | |
| PMID:22634562 | IVTH | 0.00001 M | 0.00001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| PMID:26372666 | IVR | 15 mg/kg | 15 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:26715617 | IVR | 25 mg/kg | 25 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 25 mg/kg | 25 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:30084500 | IVR | 25 mg/kg | 25 mg/kg | Increased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations |
| IVR | 25 mg/kg | 25 mg/kg | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Reduced glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increased Aspartate aminotransferase (AST) level | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| PMID:9620544 | IVR | 33 mg/kg | 33 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.